Search

Your search keyword '"Melloni, Elisabetta"' showing total 28 results

Search Constraints

Start Over You searched for: Author "Melloni, Elisabetta" Remove constraint Author: "Melloni, Elisabetta" Database Academic Search Index Remove constraint Database: Academic Search Index
Sorry, I don't understand your search. ×
28 results on '"Melloni, Elisabetta"'

Search Results

1. Evaluation of Anticancer Activity of Nucleoside–Nitric Oxide Photo-Donor Hybrids.

2. Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors.

Catalog

Books, media, physical & digital resources

3. Release of a specific set of proinflammatory adipokines by differentiating 3T3-L1 cells.

4. MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib.

5. Synthesis and Biological Investigation of Bile Acid-Paclitaxel Hybrids.

6. Autoinflammatory Diseases and Cytokine Storms—Imbalances of Innate and Adaptative Immunity.

7. Acute Neurological Involvement after Donor Lymphocyte Infusion for Post-Transplant Viral Infection: The Same Pattern of Novel Cancer Immunotherapy-Related CNS Toxicity?

8. New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib.

9. Characterization Methods for Nanoparticle–Skin Interactions: An Overview.

10. TRAIL and Ceruloplasmin Inverse Correlation as a Representative Crosstalk between Inflammation and Oxidative Stress.

11. Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.

12. The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40.

13. Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity.

14. The MDM-2 Antagonist Nutlin-3 Promotes the Maturation of Acute Myeloid Leukemic Blasts.

15. TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?

16. Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease.

17. Kinetic Profiles of Inflammatory Mediators in the Conjunctival Sac Fluid of Patients upon Photorefractive Keratectomy.

18. Human Bone Marrow Mesenchymal Stem Cells Display Anti-Cancer Activity in SCID Mice Bearing Disseminated Non-Hodgkin's Lymphoma Xenografts.

19. Conjunctival sac fluid contains elevated levels of soluble TRAIL: Implications for the anti-tumoral surveillance of the anterior surface of the eye.

20. Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70.

21. Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.

22. Extracellular Tat activates c-fos promoter in low serum-starved CD4+ T cells.

23. Mevalonate Kinase Deficiency and Squalene Synthase Inhibitor (TAK-475): The Balance to Extinguish the Inflammation.

24. MitoQ Is Able to Modulate Apoptosis and Inflammation.

25. Baseline and overtime variations of soluble adhesion molecule plasma concentrations are associated with mobility recovery after rehabilitation in multiple sclerosis patients.

26. Merkel-cell polyomavirus (MCPyV) is rarely associated to B-chronic lymphocytic leukemia (1 out of 50) samples and occurs late in the natural history of the disease

27. Colorectal Cancer Study with Nanostructured Sensors: Tumor Marker Screening of Patient Biopsies.

28. Targeting mTOR in Acute Lymphoblastic Leukemia.